Antiestrogen therapy with SERDs, particularly when administered in combination with anti-PD-L1 antibodies, acts to inhibit BC progression in part by blocking the expansion and mobilization of myeloid-derived stem cells (MDSC), suppress regulatory T cells (Tregs), and increase Th1 response [25]. This evidence concerns the gene CD274 and breast cancer.